Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico

…, DB Musante, DL Fried, BE Safirstein… - … England Journal of …, 2022 - Mass Medical Soc
Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…

[HTML][HTML] Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease

…, SH Isaacson, A Ellenbogen, BE Safirstein… - Parkinsonism & Related …, 2019 - Elsevier
Background CVT-301 (Inbrija) is a self-administered orally inhaled levodopa approved for
the intermittent treatment of OFF episodes in patients with Parkinson's disease (PD) treated …

[HTML][HTML] Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson's disease

BE Safirstein, A Ellenbogen, P Zhao, HR Henney III… - Clinical Therapeutics, 2020 - Elsevier
Purpose Levodopa (LD) is the most effective oral pharmacotherapy for the management of
motor symptoms in Parkinson's disease. However, LD use is complicated by a progressive …

Inhaled Levodopa Administered With Oral Carbidopa/Levodopa for Early Morning OFF Symptoms in Patients With Parkinson's Disease: Safety Assessment (S26. 005)

A Ellenbogen, RA Hauser, SH Isaacson, BE Safirstein… - 2018 - AAN Enterprises
Objective: Safety assessment of CVT-301 84 mg when administered with oral carbidopa/levodopa
for early morning OFF symptoms. Background: CVT-301, an investigational therapy …

Inhaled Levodopa Administered With Oral Carbidopa/Levodopa for Early Morning OFF Symptoms in Patients With Parkinson's Disease: Exploratory Efficacy Analysis …

SH Isaacson, A Ellenbogen, RA Hauser, BE Safirstein… - 2018 - AAN Enterprises
Objective: Exploratory efficacy assessment of examiner-rated time-to-ON for CVT-301 84
mg vs placebo when administered with oral carbidopa/levodopa for early morning OFF …

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study

…, GL Ahern, RF Holub, MV Farmer, BE Safirstein… - Neurology, 2012 - AAN Enterprises
Objectives: Florbetapir F 18 PET can image amyloid-β (Aβ) aggregates in the brains of living
subjects. We prospectively evaluated the prognostic utility of detecting Aβ pathology using …

[HTML][HTML] Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease

…, M Fernandez, A Kurz, O Zanetti, B Safirstein… - Alzheimer's & Dementia …, 2015 - Elsevier
Background Two previous studies of SB742457, a 5-hydroxytryptamine (5-HT 6 ) receptor
antagonist, suggested the efficacy of improvements in cognition and global outcome in …

Stroke and the american presidency

J Meschia, BE Safirstein, J Biller - Journal of Stroke and Cerebrovascular …, 1997 - Elsevier
Eight past presidents of the United States have suffered at least one stroke: John Quincy
Adams, John Tyler, Millard Fillmore, Andrew Johnson, Chester Arthur, Woodrow Wilson, …

Subregional neuroanatomical change as a biomarker for Alzheimer's disease

D Holland, JB Brewer, DJ Hagler… - Proceedings of the …, 2009 - National Acad Sciences
Regions of the temporal and parietal lobes are particularly damaged in Alzheimer's disease
(AD), and this leads to a predictable pattern of brain atrophy. In vivo quantification of …

[CITATION][C] Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico (preprint)

…, RA Riesenberg, DB Musante, DL Fried, BE Safirstein… - 2021